Charles Grob

Dr. Grob’s clinical interests include mood and anxiety disorders, as well as the self-medication hypothesis of substance abuse as it applies to substance abuse. His research has included the first FDA approved Phase 1 study of the physiological and psychological effects of MDMA (3,4-methlyenedioxymethamphetamine), a multi-national, collaborative study of the Amazonian plant hallucinogen decoction, ayahuasca, in Brazil and a pilot investigation of the safety and efficacy of psilocybin in the treatment of anxiety in adult patients with advanced-stage cancer. His most recent research has examined the safety and efficacy of an MDMA treatment model with adult autistics with severe social anxiety.